Stereotactic Accelerated Partial Breast Irradiation Using CyberKnife with Non-Invasive Skin Fiducial Marker Tracking in Early-Stage Breast Cancer: A Retrospective Study of Feasibility, Dosimetry, and Early Outcomes

By retrospective reviewing, APBI using the CyberKnife system with non-invasive skin fiducial marker tracking is a safe, precise, and effective treatment option for early-stage breast cancer. Although this retrospective study with limited follow-up demonstrated favorable dosimetric outcomes and minimal acute toxicity, further prospective studies with larger cohorts and longer observation are needed to validate these findings.